Abstract
Cutaneous adverse drug reactions (ADRs) are common. However, no prospective study assessing cutaneous ADRs is available for Chinese populations. This study aimed to assess the incidence, manifestations, causative drugs, and other factors related to cutaneous ADRs. A total of 22,866 inpatients were surveyed prospectively from January to April 2012 at the Peking Union Medical College Hospital. Only cutaneous ADRs induced by systemic drugs were considered. Fifty cases were confirmed as cutaneous ADRs, for an estimated incidence of 2.2 per 1000 during this period (95 % confidence interval 1.6–2.8). Cases of cutaneous ADRs comprised 69 % females, while 63 % of all inpatients were female (χ 2 = 0.641, P = 0.427). The department of infectious diseases was the most frequently involved department. Morbilliform exanthema (40 %) was the most frequent cutaneous ADR, followed by urticaria (23.1 %). Anti-infection drugs (36.9 %) caused most cases of cutaneous ADRs, followed by iodinated contrast media (ICM, 18.5 %) and non-steroidal anti-inflammatory drugs (NSAIDs, 18.5 %). The most frequently associated disorders were cancer (24 %), infection (22 %), cardiovascular and cerebrovascular diseases (20 %), and autoimmune diseases (18 %). In this first prospective study assessing the incidence of cutaneous ADRs in China, anti-infection drugs were the most commonly involved drugs, followed by ICM and NSAIDs. No evidence of increased cutaneous ADR incidence in AIDS or SLE patients was observed. Our findings indicate that cancer and its treatments were often related to cutaneous ADRs in China.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aceves-Avila FJ, Benites-Godinez V (2008) Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis. J Clin Rheumatol 14(5):261–263. doi:10.1097/RHU.0b013e31817a241a
Bigby M, Jick S, Jick H, Arndt K (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256(24):3358–3363
Brockow K, Christiansen C, Kanny G, Clement O, Barbaud A, Bircher A, Dewachter P, Gueant JL, Rodriguez Gueant RM, Mouton-Faivre C, Ring J, Romano A, Sainte-Laudy J, Demoly P, Pichler WJ, Enda, hypersensitivity Eigod, (2005) Management of hypersensitivity reactions to iodinated contrast media. Allergy 60(2):150–158. doi:10.1111/j.1398-9995.2005.00745.x
Chaabane H, Masmoudi A, Amouri M, Ghorbel S, Boudaya S, Hammami S, Zghal K, Turki H (2013) Cutaneous adverse drug reaction: prospective study of 118 cases. Tunis Med 91(8–9):514–520
Chen CJ, Cheng CF, Lin HY, Hung SP, Chen WC, Lin MS (2012) A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. J Clin Pharm Ther 37(6):647–651. doi:10.1111/j.1365-2710.2012.01359.x
Chen YC, Chiu HC, Chu CY (2010) Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 146(12):1373–1379. doi:10.1001/archdermatol.2010.198
Dang A, Bhandare PN (2012) The profile of voluntary reported adverse drug reactions at a tertiary care hospital: a fifteen month prospective study. J Clin Diagn Res 6(9):1504–1509. doi:10.7860/JCDR/2012/4340.2544
Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V (2003) A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 149(5):1018–1022
Halevy S, Cohen AD, Grossman N (2005) Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol 52(2):254–261. doi:10.1016/j.jaad.2004.05.006
Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R (2006) Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 37(7):899–902. doi:10.1016/j.arcmed.2006.03.010
International drug monitoring: the role of national centres. Report of a WHO meeting (1972) World Health Organ Tech Rep Ser 498:1–25
Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, Cho YS, Moon HB (2008) The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Saf 17(9):919–925. doi:10.1002/pds.1612
Pasternak JJ, Williamson EE (2012) Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist. Mayo Clin Proc 87(4):390–402. doi:10.1016/j.mayocp.2012.01.012
Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J (2003) Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 30(3):480–484
Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2(6):349–351
Sharma VK, Sethuraman G, Kumar B (2001) Cutaneous adverse drug reactions: clinical pattern and causative agents—a 6 year series from Chandigarh, India. J Postgrad Med 47(2):95–99
Ständer S, Metze D, Luger T, Schwarz T (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): a review. Hautarzt 64(8):611–622. doi:10.1007/s00105-013-2615-0 (quiz 623–614)
Thong BY, Leong KP, Tang CY, Chng HH (2003) Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 90(3):342–347. doi:10.1016/S1081-1206(10)61804-2
Thong BY, Tan TC (2011) Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71(5):684–700. doi:10.1111/j.1365-2125.2010.03774.x
Torres MJ, Gomez F, Dona I, Rosado A, Mayorga C, Garcia I, Blanca-Lopez N, Canto G, Blanca M (2012) Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. Allergy 67(7):929–935. doi:10.1111/j.1398-9995.2012.02840.x
Viera MH, Perez OA, Patel JK, Jones I, Berman B (2010) Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS. Cutis 85(6):312–317
Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, Creamer D (2013) Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 168(2):391–401. doi:10.1111/bjd.12081
Acknowledgments
We would like to thank all of the staff, residents, MD students, and nurses in Peking Union Medical College Hospital who participated in the study by collecting clinical data and completing the standard questionnaire. This work was partly funded by the National Natural Science Foundation of China (81071301) and the Natural Science Foundation of Beijing city (7132203).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical standards
This research was carried out in accordance with the Helsinki Declaration and ethical standards of the committee on human experimentation at Peking Union Medical College Hospital. The requirement for informed consent was waived as this study included only data without information about the identity of the patients.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
X.-Y. Tian and B. Liu contributed equally to this study, co-first authors.
Rights and permissions
About this article
Cite this article
Tian, XY., Liu, B., Shi, H. et al. Incidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study. Arch Dermatol Res 307, 829–834 (2015). https://doi.org/10.1007/s00403-015-1589-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-015-1589-4